HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Forum offers practical insights to meet needs of cancer survivors, overcome gaps in care Jennifer Byrne
-
- Commentary: Teaching them how to quit Nicholas J. Petrelli, MD, FACS
- Accelerated radiotherapy effective in alcohol-, tobacco-related head and neck cancer Jennifer R. Southall
- Addition of amivantamab improves PFS, response in lung cancer subset Mark Leiser
- Breast cancer expert says to dispel imposter syndrome, be authentic self on social media Jennifer R. Southall; Eleonora Teplinsky, MD
- Cancer trial toxicity reporting inconsistent, often uses ‘subjective minimizing language’ Jennifer Byrne; Bishal Gyawali, MD, PhD
- Cancers with high incidence among racial/ethnic minorities receive less research funding Jennifer R. Southall
- Combination extends survival in extensive-stage small cell lung cancer Jennifer R. Southall
- Datopotamab deruxtecan extends PFS in advanced breast cancer Drew Amorosi
-
- FDA approves Bosulif for children with chronic myelogenous leukemia
- FDA approves Ojjaara for myelofibrosis with anemia Mark Leiser
- FDA grants priority review to cervical cancer, renal cell carcinoma therapies Mark Leiser
- FDA grants regular approval to Gavreto for lung cancer subset Mark Leiser
- FDA panel: Benefit of ‘highly anticipated’ lung cancer drug can’t be interpreted reliably Mark Leiser
- FDA places formal hold on CAR-T trial paused after patient death Mark Leiser
- High-dose hyperfractionated radiotherapy improves outcomes in small cell lung cancer Mark Leiser
- Induction chemotherapy prolongs survival in locally advanced cervical cancer Mark Leiser
-
- Medical cultures converge to form evidence-based integrative oncology program Jennifer Byrne
- Neoadjuvant nivolumab improves EFS in resectable lung cancer Mark Leiser
- Osimertinib plus chemotherapy extends PFS in EGFR-mutated advanced NSCLC Jennifer R. Southall
- Pembrolizumab plus enfortumab vedotin improves survival in advanced bladder cancer Drew Amorosi
- Phase 3 trials of pembrolizumab plus lenvatinib in metastatic NSCLC miss primary endpoints Drew Amorosi
- Radioligand therapy extends PFS in neuroendocrine tumor subgroup Mark Leiser
- Regimens confer comparable OS among adolescents, young adults with ALL Mark Leiser
- Revumenib trial meets complete remission endpoint for acute leukemia subsets Drew Amorosi
-
- Rybrevant extends PFS in EGFR-mutant lung cancer Drew Amorosi
- Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer Mark Leiser
- Social determinants of health linked to poorer survival among people with blood cancers Mark Leiser
- Stereotactic radiotherapy emerges as ‘new standard’ for inoperable kidney cancer Drew Amorosi
- Supportive interventions improve endocrine therapy adherence for breast cancer survivors Jennifer Byrne; Joanna Arch, PhD
- Takeda plans withdrawal of lung cancer therapy Exkivity from U.S. market Mark Leiser
- Survey reveals 'alarming' widespread impact of chemotherapy drug shortages Jennifer R. Southall
- Barbara Ann Karmanos Cancer Institute appoints president, CEO Jennifer Byrne
-
- Immunotherapy specialist appointed research center's scientific director
- Ohio State appoints surgical oncology division chief
- Oncology, hematology physicians, researchers elected to National Academy of Medicine
- Radiation oncologist appointed to leadership role at NYU Langone’s Perlmutter Cancer Center